Transplant Flashcards
what are spectrum of CMV disease?
CMV infection with syndrome: fever, fatigue, leukopenia, low plt)
tissue invasive CMV disease: pneumonitis, hepatitis, colitis, esopahgitis, cholecystitis, duodenitis, retinitis, CNS, AKI
common timing of CMV disease?
1-4m post CRT, chorioretinitis usually late
CMV association?
acute and chronic rejection PCP, candida, aspergillus HHV6 / HHV7 reactivation HCV NODAT
Risk factor for CMV?
CMV+ donor to CMV- recipient ATG use comorbid neutropenia rejection MMF
CMV prevention?
pre-emptive: Tx if pp65 > 40
prophylaxis (if D+): 3m valgan 900 daily or 6m if depleting Ab used or D+R- (covered with ganciclovir 5mg/kg/d when induction)
Acyclovir 400mg bd x 3m if both - (for HSV)
CMV Tx?
Valgal 900mg bd
If severe / high viral load / GI absorption problem: ganciclovir 5mg/kg Q12H IV
Treat till s/s subsided, negative pp65 / QNAT / min 2 weeks
reduce immunosuppresant
2nd prophylaxis 1-3m (Valgan 450-900mg daily)
refractory CMV Tx?
IVIG
UL97: cidofovir / foscarnet
UL54: multiple drug resistance
Letemovir
ganciclovir S/E?
low WCC / plt fever, rash, seizure, nausea, myalgia dLFT, pancreatitis increase seizure with imipenem BM suppression with AZA, MPA, septrin
highest prvalance of BKV?
2-3m viruria, 3-6m viremia
cutoff for serum BK?
10000 copies /ml
BKN patho?
BK inclusion in tubular cell nuclei, glom parietal epithelium, insterstitial mononuclear inflam with plasma cell, degenerative change in tubule, focal tubulitis
BKV Tx?
reduce or stop MPA / AZA reduce CNI / steroid FK switch to CsA or SRL ? MMF to SRL or leflunomide ? cidovovir, leflunomide, FQ IVIG
BKVN + rejection Tx?
Tx acute rejection then decrease maintenance immunosuppresion
IVIG
CNI to mTOR switch or antiviral agent
Who needs INH prophylaxis?
Hx of tuberculin test+ or IFN gamme+
Hx of TB disease without adequete treatment
old granulomatous disease on CXR and epi risk factor
known prolonged exposure with active TB
In endemic areas
known history of past treated TB
What is duration of INH prophylaxis?
9 months
How to Tx MMF related GI S/E?
dose reduction
into 4 divided dose
EC MPS
fungal prophylaxis post CRT?
PO nystatin during 1st month
fluconazole if liver / pancreas Tx or after ATG
Norovirus post CRT Tx?
supportive
antimotility
reduce immunosuppresant
nitazoxanide (anti protozoan)
post CRT malignancy which are common?
EBV related: HL, NHL
HHV8 related: kaposi
HBV / HCV related: liver
HPV related: cervix, vulva, vagina, penis, anus, oral, non melanocytic skin
malignancy no need wait time for CRT?
T1 incidental RCC CIS bladder CIS cervix microscopic prostate non melanoic non metastatic skin
malignancy CI to CRT?
MM
uncontrolled CA
CA colon Duke D
CA breast stage III
PTLD common time?
1st year (median 18m) after CRT EBV- generally late (>5yr)
PTLD risk factors?
organ: kidney 1%, 33% in SB / multiple organ
Age: common in children
IC use: CNI, mTOR protective ? but conflicting results
MMF / AZA unrelated
ATG increase risk but not IL2 / CD52 alemtuzumab
balatacept (costimulatory blocker) CI if EBV-
EBV D+R-
HCV+
PTLD sym?
fever, night sweat, weight loss
respi: tonsillar / gingival, lung infection, mass
GI: diarrhea, pain, perforation, bleeding, mass
LN
CNS